{"paper_id":"4b3c8884-7ac8-4781-aee5-b40ae0ce5ab0","body_text":"Abstract\nGenetic and environmental factors influence the quality of life and well-being. Breaking of adaptive mechanisms, induced by stressors, triggers diseases. Premature ovarian insufficiency (POI) is characterized by oligo/amenorrhea, high gonadotropin, and low estradiol levels in women younger than 40 years of age. Known etiological factors inducing POI include chromosomal abnormalities, enzyme changes, autoimmune diseases, FSH receptor gene polymorphism, inhibin B mutation, infectious disease, adnexectomy, radiotherapy, uterine artery embolization, etc. Unknown factors include stressors, inflammation, telomerase shortening, biological clock acceleration, etc. Early POI symptoms, significantly decreasing the quality of life, are hot flushes, irritability, anxiety, depression, mood swings, loss of concentration, insomnia, loss of libido, etc. Late complications include cardiovascular diseases, osteoporosis, metabolic syndrome, cognitive changes, Alzheimer’s disease, urogenital dysfunction, decreased fertility rate, etc. Diagnosis is confirmed by FSH >40 IU/L (or 25 IU/L), estradiol <50 pmol/L, and oligo/amenorrhea in women younger than 40 years of age. Also, suggested analyses are AMH, inhibin B, prolactin, dehydroepiandrosterone sulfate (DHEAS), free testosterone, free thyroxin (fT4), thyroid-stimulating hormone (TSH), cortisol, vitamin D, and oral glucose tolerance test (OGTT). Visualization methods include ultrasound examination of uterus, ovaries, and breasts and osteodensitometry. In untreated POI patients, mortality rate is increased. Therapy with estroprogestogens, and all other insufficient hormones (testosterone, fT4, DHEAS, vitamin D, etc.), has to be initiated immediately and continued without age limits, depending on individual needs, in order to achieve the best quality of life.\nAccess this chapter\nTax calculation will be finalised at checkout\nPurchases are for personal use only\nSimilar content being viewed by others\nReferences\nFontana L, Kennedy BK, Longo VD, et al. Medical research: treat ageing. Nature. 2014;511:405–7. https://doi.org/10.1038/511405a.\nAlbright F, Smith PH, Fraser R. A syndrome characterized by primary ovarian insufficiency and decreased stature: report of 11 cases with a digression on hormonal control of axillary and pubic hair. Am J Med Sci. 1942;204:625–48.\nVujovic S, Brincat M, Erel T, et al. EMAS position statement: managing women with premature ovarian failure. Maturitas. 2010;67:91–3.\nNelson LM, Covington SN, Rebar RW. An update: spontaneous premature ovarian insufficiency is non early menopause. Fertil Steril. 2005;83:1327–32.\nESHRE guideline: management of women with premature ovarian insufficiency. Hum Reprod Embriol. 2016;5:926–37.\nVujovic S. Aetiology of premature ovarian failure. Menopause Int. 2009;15:72–5.\nCoulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol. 1986;67:604–6.\nLuborsky JL, Meyer P, Sowers MF, et al. Premature menopause in a multi-ethnic population study of the menopause transition. Hum Reprod. 2003;18:199–206. https://doi.org/10.1093/humrep/deg005.\nGolezar S, Ramezani TF, Khazaei S, et al. The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis. Climacteric. 2019;22:403–11. https://doi.org/10.1080/13697137.2019.1574738.\nVegetti W, Grazia Tibiletti M, et al. Inheritance in idiopathic premature ovarian failure: analysis of 71 cases. Hum Reprod. 1998;13:1796–800. https://doi.org/10.1093/humrep/13.7.1796.\nvan Kasteren YM, Hundscheid RD, Smits AP, et al. Familial idiopathic premature ovarian failure: an overrated and underestimated genetic disease? Hum Reprod. 1999;14:2455–9. https://doi.org/10.1093/humrep/14.10.2455.\nCintron D, Rodriguez-Gutierrez R, Serrano V, et al. Effect of estrogen replacement therapy on bone and cardiovascular outcomes in women with Turner syndrome: a systemic review and meta-analysis. Endocrine. 2017;55:366–75.\nQin Y, Vujovic S, et al. Ethnic specificity of the variants on the ESR1, HK3, BRSK1 genes and the 8q22.3 locus: no association with premature ovarian failure in Serbian women. Maturitas. 2014;77:64–7.\nDittmar M, Kahaly GJ. Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up. J Clin Endocrinol Metab. 2003;88:2983–92.\nHolroyd CR, Edwards CJ. The effects of hormone replacement therapy on autoimmune disease: rheumatoid arthritis and systemic lupus erythematosus. Climacteric. 2009;12:378–86.\nKirshenbaum M, Orvieto R. Premature ovarian insufficiency (POI) and autoimmunity—an update appraisal. J Assist Reprod Genet. 2019;36:2207–15.\nBunpei I. Current understanding of the etiology, symptomatology, and treatment options in premature ovarian insufficiency (POI). Front Endocrinol. 2021;12:626924. https://doi.org/10.3389/fendo.2021.626924.\nTakae S, Kawamura K, Sato Y, et al. Analysis of late-onset ovarian insufficiency after ovarian surgery: retrospective study with 75 patients of post-surgical ovarian insufficiency. PLoS One. 2014;9:e98174.\nSpears N, Lopez F, Stefansdottir A, et al. Ovarian damage from chemotherapy and current approach to its protection. Hum Reprod Update. 2019;25:673–93.\nNillson E, Klukovich R, Sadler-Riggleman I, et al. Environmental toxicants induced epigenetic transgenerational inheritance of ovarian pathology and granulosa cell epigenetics and transcriptome alterations: ancestral origins of polycystic ovary syndrome and premature ovarian insufficiency. Epigenetics. 2018;13:875–95.\nBodnar AG, Quekkette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science. 1998;16:349–52.\nSlijepcevic D, Stozinic S, Vujovic S. Stres i somatizacija. Strucna knjiga. Ur: Vlahovic Z. Beograd; 1994.\nHuang Y, Hu C, et al. Inflamm-Aging: A new mechanism affecting premature ovarian insufficiency. J Immunol Res. 2019.\nSaid S, el-Demerdash J, Tuohy VK. Autoimmune targeting disruption of pituitary-ovarian axis causes premature ovarian insufficiency. J Immunol. 2006;3:1988–98.\nSnowdon DA, Kane RL, Beeson WL, et al. Is early natural menopause a biologic marker of health and aging? Am J Public Health. 1989;79:709–13.\nHonigberg MC, Zekavat SM, Aragam K, et al. Association of premature natural and surgical menopause with incident cardiovascular disease. JAMA. 2019;322(24):2411–21.\nvan der Schouw YT, van der Graaf Y, Steyerberg EW, et al. Age at menopause as a risk factor for cardiovascular mortality. Lancet. 1996;347:714–8.\nTao XY, Zuo AZ, Wang JQ, Tao FB. Effects of primary ovarian insufficiency and early natural menopause on mortality: a meta-analysis. Climacteric. 2016;19:27–36.\nRahman H, Corcoran D, Aetesam-Ur-Rahman M, et al. Diagnosis of patients with angina and non-obstructive coronary disease in the catheter laboratory. Heart. 2019;105:1536–41.\nVan Lennep JER, Heida KV, Bots ML, Hoek A. Cardiovascular disease in women with premature ovarian insufficiency: a systematic review and meta-analysis. Eur J Prevent Cardiol. 2016;23:178–86.\nAmagai Y, Ishikawa S, Gotoh T, et al. Age at menopause and mortality in Japan. The Jichi Medical School Cohort study. J Epidemiol. 2006;16:161–8.\nGallagher LG, Davis LB, Ray RM, et al. Reproductive history and mortality from cardiovascular diseases among women textile workers in Shangai, China. Int J Epidemiol. 2011;40:1510–8.\nJacobsen BK, Knutsen SF, Fraser GE. Age at natural menopause and total mortality and mortality from ischemic heart disease: the Adventist Health Study. J Clin Epidemiol. 1999;52:303–7.\nWu X, Cai H, Kallianpur A. Impact of premature ovarian failure on mortality and morbidity among Chinese women. PLoS One. 2014;9:e89597.\nGianini A, Genazzani AR, Simoncini T. The long-term risks of premature ovarian insufficiency. In: Genazzani AR, Tarlatszis B, editors. Frontiers in gynecological endocrinology. Vol. 3. Ovarian function and reproduction—from needs to possibilities. Springer; 2016. p. 61–6.\nGerval MO, John S. Establishing the risk related to hormone replacement therapy and cardiovascular disease in women. Clin Pharm. 2017;5:7–24.\nKuylaksizoglu M, Ipeka S, Kebapcilar L, et al. Risk factors for diabetes mellitus in women with premature ovarian insufficiency. Biol Trace Elem Res. 2013;154:313–20.\nVega EM, Egoa MA, Mautalen CA. Influence of menopausal age on the severity of osteoporosis in women with vertebral fractures. Maturitas. 1994;19:117–24.\nMeczekalski B, Podfigurna-Stopa A, Genazzani AR. Hypoestrogenism in young women and its influence on bone mineral density. Gynecol Endocrinol. 2010;26:625–57.\nLana MBP, Straminsky V, Onetoo C, et al. What is really responsible for bone loss in spontaneous premature ovaria failure? A new enigma. Gynecol Endocrinol. 2010;26:755–9.\nPopat VB, Calis KA, Vanderhoot VH. Bone mineral density in estrogen deficient young women. J Clin Endocrinol Metab. 2006;54:2777–83.\nVuksanovic M, Vujovic S. Uticaj promenljivih faktora rizika za nastanak osteoporoze u zena sa prevremenom insuficijencijom ovarijuma. Beograd: Rad uze specijalizacije; 2021.\nLuine VN. Estradiol and cognitive function: past, present, future. Horm Behav. 2014;66:602–18.\nRocca WA, Grossardt BR, Shuster LT, Stewart EA. Hysterectomy, oophorectomy, estrogen, and the risk of dementia. Neurodegener Dis. 2012;10:175–8. https://doi.org/10.1159/000334764.\nPacello PC, Yelc PA, Rabelo C. Dyspareunia and lubrication in premature ovarian failure using hormone therapy and vaginal health. Clin Endocrinol. 2014;17:342–7.\nNappi RE, Cucinella L, Martini E, et al. Sexuality in premature ovarian insufficiency. Climacteric. 2019;22:289–95.\nDeAlmeida DM, Benetti-Pinto CL, Makuch MY. Sexual function of women with premature ovarian failure. Menopause. 2011;18:262–6.\nVan Kesteren YM, Schoemaher J. Premature ovarian failure: a systematic review on therapeutic interventions to restoring ovarian function and achieve pregnancy. Hum Reprod Update. 1999;5:483–92.\nLetru-Kornish H, Delaian S. Successful pregnancy after combined pentoxifylline-tocopherol treatment in women with premature ovarian failure. Fertil Steril. 2003;79:439–41.\nVujovic S, Ivovic M, Tancic Gajic M, Genazzani AR, et al. Endometrium receptivity in premature ovarian insufficiency—how to improve fertility rate and predict diseases? Gynecol Endocrinol. 2018;12:1011–5.\nHubayler ZR, Popat V, Vanderhoof VH, et al. A prospective evaluation of antral follicle function in women with 46,XX spontaneous premature ovarian insufficiency. Fertil Steril. 2010;94:1769–74.\nVujovic S, GREM. https://doi.org/10.53260-GREM.2120110. 2021.\nUysal S, Zekilsik A, Eris S, et al. Correlation of endometrial glycodelin expression and pregnancy outcome in cases with polycystic ovary syndrome treated with clomiphene citrate plus metformin: a controlled study. Obstet Gynecol Int. 2015;8:12–6.\nMamas L, Mamas E. Premature ovarian failure and dehydroepiandrosterone. Fertil Steril. 2009;91:644–6.\nJadoul P, Dolmans M, Donnez J. Fertility preservations in girls during childhood: is it feasible, efficient and safe and to whom should it be proposed? Hum Reprod Update. 2010;16:617–30.\nDragojevic Dikic S. Premature ovarian insufficiency—current hormonal approach in optimizing fertility rate—the role of melatonin. In: 18th world congress of Gynecological endocrinology. Florence; 2018.\nNICE Guideline [NG23]: menopause diagnosis and management. https://www.nice.org.uk/guidance/ng23. Last accessed 2020.\nHuhtaniemi I, Alevizaki M. Gonadotrophin resistance. Best Pract Res Clin Endocrinol Metab. 2006;20:561–76.\nBarriga PP, Montel CG. POI in adolescence:an update. Gynecol Reprod Endocrinol Metab. 2021;2:2–11.\nPanay N, Anderson RA, Nappi RE, Vincent AJ, Vujovic S, Webber L. Premature ovarian insufficiency: an International menopause society white paper. Climacteric. 2020;23:1–67.\nBaber R, Pannay N, Fenton A, International Menopause Society Writing Group. IMS recommendations in women’s midlife health and hormone replacement therapy. Climacteric. 2016;2:109–50.\nChiu T, Rogers MS, Law E, et al. Follicular fluid concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Hum Reprod. 2002;17(6):1591–6.\nCanpolat U. The association of premature ovarian insufficiency with ventricular repolarization dynamics by QT dynamicity. Europace. 2013;15:1657–63.\nDaan NMP. Cardiovascular risk in women with premature ovarian failure compared to premenopausal women at middle age. J Clin Endocinol Metab. 2016;101:3306–15.\nGoldmeier S, Angelis K, Casali KR, et al. Cardiovascular dysfunction in premature ovarian failure. Am J Transl Res. 2014;6:91–101.\nSullivan SP, Sarrel PM, Nelson LM. Hormone replacement therapy in young women with premature ovarian insufficiency and early menopause. Fertil Steril. 2016;100:1588–99.\nPearce EL. Enhance CD-8 T-cell memory by modulating fatty acid metabolism. Nature. 2009;460:103–7.\nPernicova I, Korbonis M. Metformin—mode of action and clinical implications for Diabetes and cancer. Nat Rev Endocrinol. 2014;10:577–86.\nMarina LJ, Ivovic M, Vujovic S, et al. Luteinizing hormone and insulin resistance in menopausal patients with adrenal incidentalomas. The cause-effect relationship? Clin Endocrinol. 2018;4:541–8.\nDrake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83:1032–45.\nBove R, Secor E, Chibnik LB. Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. Neurology. 2014;82:222–9.\nJanse F, Tamahatoe SJ, Eijkemans MJ, Fauser BC. Testosterone concentrations, using different assays, in different types of ovarian insufficiency: a systemic review and meta-analysis. Hum Reprod Update. 2012;18:405–19.\nWong QHY, Yeung TWY, Yung SSF, et al. The effects of 12 month dehydroepiandrosterone supplementation on the menstrual pattern, ovarian reserve and safety profiles in women with premature ovarian insufficiency. J Assist Reprod Genet. 2018;35:857–62.\nDavis SR, Baber R, Panay N, et al. Global consensus position statements on the use of testosterone therapy for women. Climacteric. 2019;22:429–34.\nTartagni M, Cicinelli E, De Pergola G, et al. Effects of pretreatment with estrogens on ovarian stimulation with gonadotropins in women with premature ovarian failure: a randomized, placebo-controlled trial. Fertil Steril. 2007;87:858–61.\nDragojevic Dikic S, Vasiljevic M, Jovanovic A, Vujovic S. Premature ovarian insufficiency—novel hormonal approach in optimizing fertility. Gynecol Endocrinol. 2020;36:162–5.\nLjubić A, Božanović T, Pirkovic-Cabarkapa A, et al. Live birth after an autologous platelet-rich plasma ovarian in vitro activation and bone marrow stem cells transplantation in a premature ovarian failure case report. Res Square. 2021:1–14. https://doi.org/10.21203/rs.3.rs-173188/v1.\nRosario R, Anderson RA. Novel approaches to fertility restoration in women with premature ovarian insufficiency. Climacteric. 2021;24(5):491–7. https://doi.org/10.1080/13697137.2020.1856806.\nSadeghi MR. Access to infertility services in middle east. J Reprod Infertil. 2015;16:179.\nLiu T, Huang Y, Chen C. Transplantation of human menstrual blood stem cells to premature ovarian failure in mouse model. Stem Cells Dev. 2014;23:1548.\nBenneti-Pinto CL, Brancalion MF, Assis LH, et al. Mammographic breast density in women with premature ovarian failure: a prospective analysis. Menopause. 2014;21:933–7.\nCollaborative Group on Hormonal Factors and Breast Cancer. Type and timing of menopausal hormone therapy risk: individual participants meta-analysis of the world-wide epidemiological evidence. Lancet. 2019;394:1159–68.\nMalone KE, Daling JR, Weiss NS. Oral contraceptives in relation to breast cancer. Epidemiol Rev. 1993;15:80–97.\nBosze P, Toth A, Toroko M. Hormone replacement and the risk of breast cancer in Turner’s syndrome. N Engl J Med. 2006;355:2599–600.\nGordhandas S, Norquist BM, Pennington KP, et al. Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA 1 and 2 mutations: a systemic review of risks and benefits. Gynecol Oncol. 2019;153:192–200.\nCarroll JS. Mechanisms of oestrogen receptor (ER) gene regulation in breast cancer. Eur J Endocrinol. 2016;175:R41–9.\nVinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the Q research and CRPRD databases. BMJ. 2019;364:k4892.\nDunselman GA, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29:400.\nCiarmela P, Ciavattini A, Giannubilo S, et al. Management of leiomyomas in perimenopausal women. Maturitas. 2014;78:168–73.\nVujovic S, Ivovic M, Tancic Gajic M, et al. Chapter 5: Premature ovarian insufficiency: optimizing quality of life and long term effects. In: Frontiers in gynecological endocrinology. 2020. p. 38–47.\nAuthor information\nAuthors and Affiliations\nEditor information\nEditors and Affiliations\nRights and permissions\nCopyright information\n© 2023 International Society of Gynecological Endocrinology\nAbout this chapter\nCite this chapter\nVujovic, S., Ivovic, M., Tancic Gajic, M., Marina, L., Dragojevic-Dikic, S. (2023). Premature Ovarian Insufficiency. In: Genazzani, A.R., Hirschberg, A.L., Genazzani, A.D., Nappi, R., Vujovic, S. (eds) Amenorrhea. ISGE Series. Springer, Cham. https://doi.org/10.1007/978-3-031-22378-5_11\nDownload citation\nDOI: https://doi.org/10.1007/978-3-031-22378-5_11\nPublished:\nPublisher Name: Springer, Cham\nPrint ISBN: 978-3-031-22377-8\nOnline ISBN: 978-3-031-22378-5\neBook Packages: MedicineMedicine (R0)","source_license":"CC0","license_restricted":false}